Which has higher valuation & earnings, ZBH or LQDA?

Zimmer Biomet has higher revenue and earnings than Liquidia. Zimmer Biomet is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zimmer Biomet $8.23B 1.94 $705.20M $3.85 21.42 Liquidia $158.32M 34.71 -$68.92M $0.14 441.32

Is ZBH or LQDA more profitable?

Zimmer Biomet has a net margin of 9.05% compared to Liquidia's net margin of 7.74%. Liquidia's return on equity of 46.82% beat Zimmer Biomet's return on equity. Company Net Margins Return on Equity Return on Assets Zimmer Biomet 9.05% 13.24% 7.28% Liquidia 7.74% 46.82% 7.06%

Does the media favor ZBH or LQDA?

In the previous week, Liquidia had 4 more articles in the media than Zimmer Biomet. MarketBeat recorded 15 mentions for Liquidia and 11 mentions for Zimmer Biomet. Zimmer Biomet's average media sentiment score of 1.14 beat Liquidia's score of 0.37 indicating that Zimmer Biomet is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zimmer Biomet 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Liquidia 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, LQDA or SOLV?

Solventum has higher revenue and earnings than Liquidia. Solventum is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liquidia $158.32M 34.71 -$68.92M $0.14 441.32 Solventum $8.33B 1.56 $1.56B $8.16 9.21

Is LQDA or SOLV more profitable?

Solventum has a net margin of 17.33% compared to Liquidia's net margin of 7.74%. Liquidia's return on equity of 46.82% beat Solventum's return on equity. Company Net Margins Return on Equity Return on Assets Liquidia 7.74% 46.82% 7.06% Solventum 17.33% 23.51% 7.63%

Does the media refer more to LQDA or SOLV?

In the previous week, Liquidia had 11 more articles in the media than Solventum. MarketBeat recorded 15 mentions for Liquidia and 4 mentions for Solventum. Liquidia's average media sentiment score of 0.37 beat Solventum's score of 0.30 indicating that Liquidia is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Solventum 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, LQDA or SNN?

Smith & Nephew SNATS has higher revenue and earnings than Liquidia. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liquidia $158.32M 34.71 -$68.92M $0.14 441.32 Smith & Nephew SNATS $6.16B 2.06 $625M N/A N/A

Does the media refer more to LQDA or SNN?

In the previous week, Liquidia had 14 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 15 mentions for Liquidia and 1 mentions for Smith & Nephew SNATS. Liquidia's average media sentiment score of 0.37 beat Smith & Nephew SNATS's score of 0.00 indicating that Liquidia is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Smith & Nephew SNATS 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, LQDA or PEN?

Penumbra has higher revenue and earnings than Liquidia. Penumbra is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liquidia $158.32M 34.71 -$68.92M $0.14 441.32 Penumbra $1.40B 8.92 $177.69M $4.34 73.38

Is LQDA or PEN more profitable?

Penumbra has a net margin of 11.76% compared to Liquidia's net margin of 7.74%. Liquidia's return on equity of 46.82% beat Penumbra's return on equity. Company Net Margins Return on Equity Return on Assets Liquidia 7.74% 46.82% 7.06% Penumbra 11.76% 10.87% 8.45%

Does the media prefer LQDA or PEN?

In the previous week, Liquidia had 11 more articles in the media than Penumbra. MarketBeat recorded 15 mentions for Liquidia and 4 mentions for Penumbra. Penumbra's average media sentiment score of 1.36 beat Liquidia's score of 0.37 indicating that Penumbra is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Penumbra 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, LQDA or GKOS?

Liquidia has higher earnings, but lower revenue than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liquidia $158.32M 34.71 -$68.92M $0.14 441.32 Glaukos $507.44M 11.93 -$187.69M -$3.28 N/A

Is LQDA or GKOS more profitable?

Liquidia has a net margin of 7.74% compared to Glaukos' net margin of -34.34%. Liquidia's return on equity of 46.82% beat Glaukos' return on equity. Company Net Margins Return on Equity Return on Assets Liquidia 7.74% 46.82% 7.06% Glaukos -34.34% -6.92% -5.25%

Does the media prefer LQDA or GKOS?

In the previous week, Liquidia had 13 more articles in the media than Glaukos. MarketBeat recorded 15 mentions for Liquidia and 2 mentions for Glaukos. Glaukos' average media sentiment score of 0.75 beat Liquidia's score of 0.37 indicating that Glaukos is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Glaukos 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Liquidia (LQDA) Competitors

$61.78 -0.08 (-0.12%)

Closing price 05/29/2026 03:59 PM Eastern

Extended Trading

$61.85 +0.07 (+0.11%)

As of 05/29/2026 06:51 PM Eastern

Compare

LQDA vs. ZBH, SOLV, SNN, PEN, and GKOS

Should you buy Liquidia stock or one of its competitors? MarketBeat compares Liquidia with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Liquidia include Zimmer Biomet (ZBH), Solventum (SOLV), Smith & Nephew SNATS (SNN), Penumbra (PEN), and Glaukos (GKOS). These companies are all part of the "medical equipment" industry.

How does Liquidia compare to Zimmer Biomet?

Zimmer Biomet (NYSE:ZBH) and Liquidia (NASDAQ:LQDA) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, media sentiment and profitability.

Zimmer Biomet presently has a consensus price target of $102.70, suggesting a potential upside of 24.55%. Liquidia has a consensus price target of $50.88, suggesting a potential downside of 17.66%. Given Zimmer Biomet's higher possible upside, analysts plainly believe Zimmer Biomet is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zimmer Biomet	3 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.26
Liquidia	2 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.91

In the previous week, Liquidia had 4 more articles in the media than Zimmer Biomet. MarketBeat recorded 15 mentions for Liquidia and 11 mentions for Zimmer Biomet. Zimmer Biomet's average media sentiment score of 1.14 beat Liquidia's score of 0.37 indicating that Zimmer Biomet is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zimmer Biomet	7 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Liquidia	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zimmer Biomet has higher revenue and earnings than Liquidia. Zimmer Biomet is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zimmer Biomet	$8.23B	1.94	$705.20M	$3.85	21.42
Liquidia	$158.32M	34.71	-$68.92M	$0.14	441.32

Zimmer Biomet has a beta of 0.47, indicating that its stock price is 53% less volatile than the broader market. Comparatively, Liquidia has a beta of 0.57, indicating that its stock price is 43% less volatile than the broader market.

Zimmer Biomet has a net margin of 9.05% compared to Liquidia's net margin of 7.74%. Liquidia's return on equity of 46.82% beat Zimmer Biomet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zimmer Biomet	9.05%	13.24%	7.28%
Liquidia	7.74%	46.82%	7.06%

88.9% of Zimmer Biomet shares are held by institutional investors. Comparatively, 64.5% of Liquidia shares are held by institutional investors. 1.3% of Zimmer Biomet shares are held by insiders. Comparatively, 25.6% of Liquidia shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Zimmer Biomet beats Liquidia on 9 of the 17 factors compared between the two stocks.

How does Liquidia compare to Solventum?

Liquidia (NASDAQ:LQDA) and Solventum (NYSE:SOLV) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

Solventum has higher revenue and earnings than Liquidia. Solventum is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	34.71	-$68.92M	$0.14	441.32
Solventum	$8.33B	1.56	$1.56B	$8.16	9.21

Liquidia presently has a consensus price target of $50.88, suggesting a potential downside of 17.66%. Solventum has a consensus price target of $84.25, suggesting a potential upside of 12.14%. Given Solventum's higher probable upside, analysts clearly believe Solventum is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.91
Solventum	1 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50

Solventum has a net margin of 17.33% compared to Liquidia's net margin of 7.74%. Liquidia's return on equity of 46.82% beat Solventum's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	7.74%	46.82%	7.06%
Solventum	17.33%	23.51%	7.63%

64.5% of Liquidia shares are held by institutional investors. 25.6% of Liquidia shares are held by company insiders. Comparatively, 0.2% of Solventum shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Liquidia has a beta of 0.57, meaning that its share price is 43% less volatile than the broader market. Comparatively, Solventum has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market.

In the previous week, Liquidia had 11 more articles in the media than Solventum. MarketBeat recorded 15 mentions for Liquidia and 4 mentions for Solventum. Liquidia's average media sentiment score of 0.37 beat Solventum's score of 0.30 indicating that Liquidia is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Solventum	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Liquidia beats Solventum on 9 of the 17 factors compared between the two stocks.

How does Liquidia compare to Smith & Nephew SNATS?

Liquidia (NASDAQ:LQDA) and Smith & Nephew SNATS (NYSE:SNN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

64.5% of Liquidia shares are owned by institutional investors. Comparatively, 25.6% of Smith & Nephew SNATS shares are owned by institutional investors. 25.6% of Liquidia shares are owned by insiders. Comparatively, 1.0% of Smith & Nephew SNATS shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Liquidia currently has a consensus target price of $50.88, indicating a potential downside of 17.66%. Smith & Nephew SNATS has a consensus target price of $30.93, indicating a potential upside of 4.07%. Given Smith & Nephew SNATS's higher possible upside, analysts plainly believe Smith & Nephew SNATS is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.91
Smith & Nephew SNATS	0 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Smith & Nephew SNATS has higher revenue and earnings than Liquidia.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	34.71	-$68.92M	$0.14	441.32
Smith & Nephew SNATS	$6.16B	2.06	$625M	N/A	N/A

Liquidia has a net margin of 7.74% compared to Smith & Nephew SNATS's net margin of 0.00%. Liquidia's return on equity of 46.82% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	7.74%	46.82%	7.06%
Smith & Nephew SNATS	N/A	N/A	N/A

Liquidia has a beta of 0.57, indicating that its share price is 43% less volatile than the broader market. Comparatively, Smith & Nephew SNATS has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market.

In the previous week, Liquidia had 14 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 15 mentions for Liquidia and 1 mentions for Smith & Nephew SNATS. Liquidia's average media sentiment score of 0.37 beat Smith & Nephew SNATS's score of 0.00 indicating that Liquidia is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Smith & Nephew SNATS	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Liquidia beats Smith & Nephew SNATS on 12 of the 15 factors compared between the two stocks.

How does Liquidia compare to Penumbra?

Liquidia (NASDAQ:LQDA) and Penumbra (NYSE:PEN) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.

In the previous week, Liquidia had 11 more articles in the media than Penumbra. MarketBeat recorded 15 mentions for Liquidia and 4 mentions for Penumbra. Penumbra's average media sentiment score of 1.36 beat Liquidia's score of 0.37 indicating that Penumbra is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Penumbra	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Penumbra has higher revenue and earnings than Liquidia. Penumbra is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	34.71	-$68.92M	$0.14	441.32
Penumbra	$1.40B	8.92	$177.69M	$4.34	73.38

Penumbra has a net margin of 11.76% compared to Liquidia's net margin of 7.74%. Liquidia's return on equity of 46.82% beat Penumbra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	7.74%	46.82%	7.06%
Penumbra	11.76%	10.87%	8.45%

Liquidia presently has a consensus price target of $50.88, indicating a potential downside of 17.66%. Penumbra has a consensus price target of $361.33, indicating a potential upside of 13.46%. Given Penumbra's higher possible upside, analysts plainly believe Penumbra is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.91
Penumbra	0 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18

Liquidia has a beta of 0.57, suggesting that its share price is 43% less volatile than the broader market. Comparatively, Penumbra has a beta of 0.71, suggesting that its share price is 29% less volatile than the broader market.

64.5% of Liquidia shares are owned by institutional investors. Comparatively, 88.9% of Penumbra shares are owned by institutional investors. 25.6% of Liquidia shares are owned by insiders. Comparatively, 2.9% of Penumbra shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Penumbra beats Liquidia on 9 of the 17 factors compared between the two stocks.

How does Liquidia compare to Glaukos?

Liquidia (NASDAQ:LQDA) and Glaukos (NYSE:GKOS) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

Liquidia has a beta of 0.57, suggesting that its share price is 43% less volatile than the broader market. Comparatively, Glaukos has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market.

Liquidia has a net margin of 7.74% compared to Glaukos' net margin of -34.34%. Liquidia's return on equity of 46.82% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	7.74%	46.82%	7.06%
Glaukos	-34.34%	-6.92%	-5.25%

64.5% of Liquidia shares are owned by institutional investors. Comparatively, 99.0% of Glaukos shares are owned by institutional investors. 25.6% of Liquidia shares are owned by company insiders. Comparatively, 5.9% of Glaukos shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Liquidia had 13 more articles in the media than Glaukos. MarketBeat recorded 15 mentions for Liquidia and 2 mentions for Glaukos. Glaukos' average media sentiment score of 0.75 beat Liquidia's score of 0.37 indicating that Glaukos is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Glaukos	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Liquidia has higher earnings, but lower revenue than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	34.71	-$68.92M	$0.14	441.32
Glaukos	$507.44M	11.93	-$187.69M	-$3.28	N/A

Liquidia presently has a consensus target price of $50.88, indicating a potential downside of 17.66%. Glaukos has a consensus target price of $146.17, indicating a potential upside of 41.80%. Given Glaukos' higher possible upside, analysts clearly believe Glaukos is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.91
Glaukos	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

Summary

Liquidia beats Glaukos on 11 of the 17 factors compared between the two stocks.

Get Liquidia News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LQDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LQDA vs. The Competition

Export

Metric	Liquidia	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.49B	$3.40B	$6.41B	$12.57B
Dividend Yield	N/A	2.29%	2.68%	5.31%
P/E Ratio	441.35	18.88	21.61	26.27
Price / Sales	34.71	334.85	561.77	114.93
Price / Cash	N/A	54.19	27.44	37.60
Price / Book	121.15	6.93	10.04	6.86
Net Income	-$68.92M	$24.20M	$3.56B	$337.26M
7 Day Performance	1.32%	4.11%	2.82%	3.58%
1 Month Performance	N/A	N/A	N/A	-0.79%
1 Year Performance	311.08%	66.00%	37.62%	39.67%

Liquidia Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LQDA Liquidia	2.4732 of 5 stars	$61.79 -0.1%	$50.88 -17.7%	+311.1%	$5.49B	$158.32M	441.35	50
ZBH Zimmer Biomet	4.7726 of 5 stars	$85.41 -0.1%	$102.80 +20.4%	-10.5%	$16.54B	$8.23B	22.19	17,000	Positive News
SOLV Solventum	3.2439 of 5 stars	$76.92 +0.1%	$84.25 +9.5%	+2.9%	$13.31B	$8.33B	9.43	20,000
SNN Smith & Nephew SNATS	1.8792 of 5 stars	$30.51 -0.1%	$30.93 +1.4%	+2.6%	$13.04B	$6.16B	N/A	16,988
PEN Penumbra	2.228 of 5 stars	$328.46 -0.1%	$361.33 +10.0%	+19.1%	$12.93B	$1.40B	75.68	4,700	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LQDA) was last updated on 6/1/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Liquidia (LQDA) Competitors

LQDA vs. ZBH, SOLV, SNN, PEN, and GKOS

How does Liquidia compare to Zimmer Biomet?

Summary

How does Liquidia compare to Solventum?

Summary

How does Liquidia compare to Smith & Nephew SNATS?

Summary

How does Liquidia compare to Penumbra?

Summary

How does Liquidia compare to Glaukos?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LQDA vs. The Competition

Liquidia Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Liquidia (LQDA) Competitors

LQDA vs. ZBH, SOLV, SNN, PEN, and GKOS

How does Liquidia compare to Zimmer Biomet?

Do analysts rate ZBH or LQDA?

Does the media favor ZBH or LQDA?

Which has higher valuation & earnings, ZBH or LQDA?

Which has more volatility & risk, ZBH or LQDA?

Is ZBH or LQDA more profitable?

Do institutionals and insiders hold more shares of ZBH or LQDA?

Summary

How does Liquidia compare to Solventum?

Which has higher earnings & valuation, LQDA or SOLV?

Do analysts prefer LQDA or SOLV?

Is LQDA or SOLV more profitable?

Do institutionals and insiders have more ownership in LQDA or SOLV?

Which has more volatility and risk, LQDA or SOLV?

Does the media refer more to LQDA or SOLV?

Summary

How does Liquidia compare to Smith & Nephew SNATS?

Do institutionals and insiders believe in LQDA or SNN?

Do analysts recommend LQDA or SNN?

Which has stronger earnings and valuation, LQDA or SNN?

Is LQDA or SNN more profitable?

Which has more risk & volatility, LQDA or SNN?

Does the media refer more to LQDA or SNN?

Summary

How does Liquidia compare to Penumbra?

Does the media prefer LQDA or PEN?

Which has preferable earnings and valuation, LQDA or PEN?

Is LQDA or PEN more profitable?

Do analysts prefer LQDA or PEN?

Which has more risk & volatility, LQDA or PEN?

Do institutionals and insiders believe in LQDA or PEN?

Summary

How does Liquidia compare to Glaukos?

Which has more risk and volatility, LQDA or GKOS?

Is LQDA or GKOS more profitable?

Do institutionals & insiders believe in LQDA or GKOS?

Does the media prefer LQDA or GKOS?

Which has stronger valuation and earnings, LQDA or GKOS?

Do analysts prefer LQDA or GKOS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LQDA vs. The Competition

Liquidia Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools